Recruiting studies: Refractory And Or Relapsed Metastatic Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994 A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT04794972 Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S
Phase 1/Phase 2 · 39 location(s) · ModernaTX, Inc. · NCT05533697 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494 Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 · 3 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT01804634 First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Phase 1 · 10 location(s) · EpimAb Biotherapeutics (Suzhou)Co., Ltd. · NCT05607498 A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Stingray Therapeutics · NCT06063681 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499 Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT05631886 CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Phase 1/Phase 2 · 35 location(s) · Children's Oncology Group · NCT04870944

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.